Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-26T03:11:05.404Z Has data issue: false hasContentIssue false
  • English
  • Français

Olanzapine as medication of first choice in therapy-resistant schizophrenia?

Published online by Cambridge University Press:  18 September 2015

J. à Campo ,
H. Nijman  and
H. Merckelbach
J. à Campo*
Affiliation:
Psychiatric Hospital Welterhof, Heerlen, The Netherlands
H. Nijman
Affiliation:
Psychiatric Hospital Welterhof, Heerlen, The Netherlands Department of Psychology, Maastricht University, Maastricht, The Netherlands
H. Merckelbach
Affiliation:
Department of Psychology, Maastricht University, Maastricht, The Netherlands
*
Psychiatrisch Centrum Welterhof, P.O. Box 4436, 6401 CX Heerlen, The Netherlands
Get access Rights & Permissions [Opens in a new window]

Summary

A case history of a thirty-one year old schizophrenic female who was treated with olanzapine is described. Olanzapine is a relatively new atypical antipsychotic drug with a dopamine antagonistic as well as a potent serotonine antagonistic effect. Olanzapine was prescribed effectively after haloperidol, flupentixol chloride, and clozapine had not lead to (lasting) improvements of the psychiatric condition of the patient. Considering the efficacy and the limited risks of this relatively new antipsychotic medication the question arises as to whether olanzapine should be considered as the drug of first choice for patients who do not benefit from treatment with a typical neuroleptic drug.

Keywords

Olanzapinetherapy-resistant schizophreniaOlanzapinetherapie-resistente schizofrenie
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 10 , Issue 3 , September 1998 , pp. 78 - 82
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literature

1.Brenner, HD, Dencker, SJ, Goldstein, MJ, et al.Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990; 16: 551–62.CrossRefGoogle ScholarPubMed
2.Dev, VJ, Krupp, R. Adverse event profile and safety of clozapine. Rev contemp Pharmacother 1995; 6: 197–207.Google Scholar
3.Beasley, CM, Sanger, T, Satterlee, W, et al.Olanzapine versus placebo: results of a double-blind fixed dose olanzapine trial. Psychopharmacology 1996; 124: 159–67.CrossRefGoogle ScholarPubMed
4.Beasley, CM, Tollefson, G, Tran, P, et al.Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111–24CrossRefGoogle ScholarPubMed
5.Tollefson, GD, Beasley, CM, Tran, PV, et al.Olanzapine versus haloperidol in treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiat 1997; 154: 457–65.Google ScholarPubMed
6.Campo, J à, Nijman, H, Merckelbach, H. Intermittent neuroleptic treatment of therapy-resistant schizophrenic psychoses. Eur J Psychiat 1997; 11:69–71.Google Scholar
7.Kay, SR, Opler, LA, Fiszbein, A. Positive and negative syndrome scale (PANSS) rating manual. Department of Psychiatry, Albert Einstein College of Medicine, Montefiore Medical Centre, and Schizophrenia Research Unit, Bronx Psychiatric Centre, 1986.Google Scholar